May 18, 2020
FDA approves Genentech’s Tecentriq for certain metastatic lung cancer patients
– Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall – – Approval…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Tecentriq
October 21, 2019
Genentech’s Tecentriq combo with Avastin increases overall survival in people with Unresectable Hepatocellular Carcinoma
Genentech’s Tecentriq’s First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the…
September 30, 2019
Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer
– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced…
September 27, 2019
Genentech’s Tecentriq (Atezolizumab) Improves Overall Survival as a First-line Monotherapy in Certain People With Advanced Non-small Cell Lung Cancer
– Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1…
September 12, 2019
Roche’s Tecentriq shows survival benefit over chemotherapy as an initial treatment in NSCLC
Roche’s study met a goal, comparing a lung cancer therapy Tecentriq with cisplatin and pemetrexed as the initial monotherapy compared in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT).
August 5, 2019
Genentech’s Tecentriq combined with Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer
– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer…
March 19, 2019
FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),today announced that the U.S. Food and Drug Administration (FDA)approved Tecentriq® (atezolizumab), in combinationwith carboplatin and etoposide (chemotherapy), for the initial(first-line) treatment of adults with extensive-stage small cell lungcancer (ES-SCLC).
March 11, 2019
Tecentriq combination fast approval for PD-L1-positive, metastatic triple-negative breast cancer
Roche said Monday it got accelerated approval to Tecentriq plus chemotherapy for the treatment of adults with unresectable triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test.
March 7, 2019
Syndax expects milestone-rich time ahead
Syndax Pharmaceutical expects the coming months to be a very exciting, milestone-rich, said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, in a press release Thursday, reporting financial results, fourth quarter ended December 31, 2018.
January 27, 2017
Roche cancer drug taking bite out of Bristol’s Opdivo
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker’s treatment is making up lost ground.